Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

Introduction Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluzole and edaravone have been approved by...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: William Huynh, Steve Vucic, Parvathi Menon, Austin Rynders, Karen S Ho, Robert Glanzman, Michael T Hotchkin
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
R
Acceso en línea:https://doaj.org/article/5b34b89dba1c4672a117a2d5413de1b6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!